GLP-2(3-33)|cas:275801-62-2|西域试剂

GLP-2(3-33),99.88%

产品编号：Bellancom-P2625| CAS NO：275801-62-2| 分子式：C₁₅₆H₂₄₂N₄₀O₅₃S| 分子量：3557.89

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P2625		￥2900.00	杭州北京（现货）
Bellancom-P2625		￥8700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GLP-2(3-33)

产品介绍

GLP-2(3-33) 由二肽基肽酶 IV (DPPIV) 产生，是一种 GLP-2 受体部分激动剂 (EC₅₀=5.8 nM)。

生物活性

GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM).

体外研究

GLP-2 is secreted as a 33-amino acid peptide, but is rapidly degraded at an N-terminus site to GLP-2(3-33) in circulation, in large part, by dipeptidylpeptidase IV (DPPIV). GLP-2 (3-33) acts as a partial agonist with potential competitive antagonistic properties on the GLP-2 receptor. In the GLP-2 receptor-binding assay, the binding IC₅₀ for GLP-2 1–33 was 3.1 nM, and it was 41 nM for GLP-2 3-33. Thus, GLP-2 3–33 had 7.5% binding affinity compared to GLP-2 1-33.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

GLP-2(3-33) (60 ng; once a day i.p. for 4 weeks) increases dyslipidemia and hepatic lipid accumulation in HFD-fed mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J (B6) mice (HFD)
Dosage:	60 ng
Administration:	Once a day i.p. for 4 weeks
Result:	Significantly affected plasma lipids; Showed increase of triglycerides and cholesterol and reduction of HDL; Significantly increased plasma ALT and AST and intrahepatic lipid concentration.

体内研究

GLP-2(3-33) (60 ng; once a day i.p. for 4 weeks) increases dyslipidemia and hepatic lipid accumulation in HFD-fed mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J (B6) mice (HFD)
Dosage:	60 ng
Administration:	Once a day i.p. for 4 weeks
Result:	Significantly affected plasma lipids; Showed increase of triglycerides and cholesterol and reduction of HDL; Significantly increased plasma ALT and AST and intrahepatic lipid concentration.